0001209191-23-049797.txt : 20230918 0001209191-23-049797.hdr.sgml : 20230918 20230918174534 ACCESSION NUMBER: 0001209191-23-049797 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230915 FILED AS OF DATE: 20230918 DATE AS OF CHANGE: 20230918 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Perlich Irene CENTRAL INDEX KEY: 0001989954 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38853 FILM NUMBER: 231262000 MAIL ADDRESS: STREET 1: C/O NGM BIOPHARMACEUTICALS, INC. STREET 2: 333 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NGM BIOPHARMACEUTICALS INC CENTRAL INDEX KEY: 0001426332 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 333 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-243-5555 MAIL ADDRESS: STREET 1: 333 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2023-09-15 0 0001426332 NGM BIOPHARMACEUTICALS INC NGM 0001989954 Perlich Irene C/O NGM BIOPHARMACEUTICALS, INC. 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Principal Accounting Officer Common Stock 10000 D Stock Option (Right to Buy) 29.62 2031-03-31 Common Stock 50000 D Stock Option (Right to Buy) 15.20 2032-03-02 Common Stock 35000 D Stock Option (Right to Buy) 5.36 2032-11-03 Common Stock 17500 D Stock Option (Right to Buy) 4.36 2033-03-01 Common Stock 30000 D Represents shares of common stock issuable upon the vesting and settlement of restricted stock units ("RSUs"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027. The shares subject to the option shall vest over a four-year period commencing March 22, 2021, with 1/4th of the shares vesting on March 22, 2022 and 1/48th of the shares vesting monthly thereafter. The shares subject to the option shall vest over a four-year period commencing January 1, 2022, with 1/48th of the shares vesting on a monthly basis. The shares subject to the option shall vest over a two-year period commencing November 4, 2022, with 1/2 of the shares vesting on an annual basis. The shares subject to the option shall vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis. /s/ Valerie Pierce, Attorney-in-fact 2023-09-18 EX-24 2 poa.txt POA DOCUMENT POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of David J. Woodhouse, Siobhan Nolan Mangini and Valerie Pierce, or any of them signing singly, and with full power of substitution, the undersigned's true and lawful attorney in fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or more than 10% stockholder of NGM Biopharmaceuticals, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney in fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney in fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney in fact may approve in such attorney in fact's discretion. The undersigned hereby grants to each such attorney in fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney in fact, or such attorney in fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys in fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys in fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of August 15, 2023. /s/ Irene Perlich